Fox Run Management L.L.C. Increases Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Fox Run Management L.L.C. grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 41.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 55,062 shares of the biopharmaceutical company’s stock after purchasing an additional 16,084 shares during the quarter. Fox Run Management L.L.C.’s holdings in Royalty Pharma were worth $1,405,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in RPRX. Keene & Associates Inc. grew its holdings in shares of Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 370 shares during the last quarter. Blue Trust Inc. lifted its position in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 376 shares during the period. Sanctuary Advisors LLC grew its stake in shares of Royalty Pharma by 0.9% in the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock valued at $1,068,000 after purchasing an additional 388 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Royalty Pharma by 0.5% in the 4th quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company’s stock valued at $2,822,000 after purchasing an additional 537 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Royalty Pharma by 31.4% in the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 590 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $33.70 on Friday. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a 50 day simple moving average of $32.25 and a 200-day simple moving average of $28.72. The company has a market cap of $19.43 billion, a price-to-earnings ratio of 23.24, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a yield of 2.61%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s payout ratio is currently 60.69%.

Analysts Set New Price Targets

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.